Clinical next generation sequencing (NGS) transforms the way we care for patients and has the potential to significantly reduce costs in our over-burdened healthcare system. Yet for various reasons coverage and reimbursement of these tests remain obstacles for many laboratories that aim to provide them. In this informative webinar, PierianDx and Boston Healthcare dissect the evolving landscape of NGS test reimbursement. We will provide a toolkit that enables molecular diagnostic laboratories to demonstrate the clinical utility of a test, effectively bill for the test, and communicate value to payors--all to improve reimbursement.
By attending this webinar, you will learn about:
Presenter: Joseph Ferrara, President, Boston Healthcare
Moderator: Michael L. Sanderson, CEO, PierianDx